Brenus Pharma is a French clinical-stage biotech developing a pioneering technology platform, Stimulated-Tumor-Cell (STC) designed to generate 'first-in-class', 'off-the-shelf' therapeutic cancer vaccine leading the way to a new precision medicine in immuno-oncology. 🧬STC mimics the relapse conditions of patients' tumor cells to educate their immune systems to be able to anticipate, target and destroy these tumor cells as soon as they appear and regardless of theur evolution. Brenus Pharma is on the brink of a breakthrough and will start its first-in-human study in 2024 in colorectal cancer (mCRC), 2nd cause of cancer-related deaths wordlwide. We are building a strong portfolio in solid tumors, leveraging our STC platform, to change a paradigm in oncology by making patients once again actors in their treatment. 🚀DARE TO INNOVATE 🚀
Total raised: $25M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.09.2024 | Series A | $25M | - |
Mentions in press and media 5
| Date | Title | Description |
| 20.09.2024 | Brenus Pharma: $25 Million (Series A) Closed To Develop Cancer Vaccines | Brenus Pharma, a biotech company specializing in cancer vaccine development, announced the completion of a $25 million Series A funding round. This funding round was led by Angelor, an investment fund bringing together a cluster of investor... |
| 18.09.2024 | Brenus Pharma: A New Dawn in Cancer Vaccines | In the world of biotechnology, every breakthrough is a beacon of hope. Brenus Pharma, a Lyon-based biotech company, has recently raised €22.2 million (approximately $25 million) in a Series A funding round. This infusion of capital is not j... |
| 18.09.2024 | Brenus Pharma Raises $25M in Series A Funding | Brenus Pharma, a Lyon, France-based biotech company specializing in the development of cancer vaccines, raised $25M in Series A Funding. The round was led by Angelor, with participation from UI Investissement, Crédit Agricole Centre-France ... |
| 18.09.2024 | Lyon-based Brenus Pharma raises €22.2 million for precision cancer vaccines | Brenus Pharma, a French biotech company specializing in the development of cancer vaccines, announced the completion of a €22.2 million Series A financing round. The round is led by Angelor, an investment fund bringing together a cluster of... |
| - | Brenus Pharma | “Brenus Pharma” |